Nikolai Podoltsev, MD, PhD
Associate Professor of Internal Medicine (Hematology)Cards
Appointments
Additional Titles
Duffy Firm Chief for Education, Department of Internal Medicine
Associate Director of the Hematology/Oncology Fellowship Program, Department of Internal Medicine
Clinical Director, Malignant Hematology, Department of Internal Medicine, Division of Malignant Hematology
Contact Info
Appointments
Additional Titles
Duffy Firm Chief for Education, Department of Internal Medicine
Associate Director of the Hematology/Oncology Fellowship Program, Department of Internal Medicine
Clinical Director, Malignant Hematology, Department of Internal Medicine, Division of Malignant Hematology
Contact Info
Appointments
Additional Titles
Duffy Firm Chief for Education, Department of Internal Medicine
Associate Director of the Hematology/Oncology Fellowship Program, Department of Internal Medicine
Clinical Director, Malignant Hematology, Department of Internal Medicine, Division of Malignant Hematology
Contact Info
About
Titles
Associate Professor of Internal Medicine (Hematology)
Duffy Firm Chief for Education, Department of Internal Medicine; Associate Director of the Hematology/Oncology Fellowship Program, Department of Internal Medicine; Clinical Director, Malignant Hematology, Department of Internal Medicine, Division of Malignant Hematology
Biography
Dr. Nikolai Podoltsev is an Associate Professor of Medicine (Hematology). His practice is focused on management of patients with acute leukemias, including acute myeloid leukemias (AML) and acute lymphoblastic leukemia (ALL) as well as myeloid neoplasms like myelodisplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs), such as polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), and chronic myeloid leukemia (CML) among others. He also provides care for patients with aplastic anemia and bone marrow failure syndromes and follows patients with clonal hematopoiesis of indeterminate potential (CHIP), and systemic mastocytosis and hypereosinophilic syndrome. He is the director of the Hematology/Leukemia Tumor Board.
As the Associate Director of the Yale Hematology/Oncology Fellowship Program and Yale-New Haven Hospital Duffy Firm Chief for Education, Dr. Podoltsev is involved in organizing and providing hematology education for hematology/medical oncology fellows, internal medicine residents, and medical students. The Yale Cancer Outcomes Public Policy and Effectiveness Research (COPPER) Center membership helps Dr. Podoltsev to study epidemiology, and the patterns of care and outcomes of patients with hematological malignancies. Dr. Podoltsev is engaged in the clinical research programs of the Leukemia Clinical Research Team as a Principal Investigator for multiple clinical trials enrolling patients with acute leukemias and myeloid malignancies.
Appointments
Hematology
Associate Professor on TermPrimary
Other Departments & Organizations
- Developmental Therapeutics
- Hematology
- Internal Medicine
- Leukemia & Lymphoma Program
- Yale Cancer Center
- Yale Medicine
- Yale Ventures
Education & Training
- Fellow
- Yale University School of Medicine (2010)
- Chief Resident
- Hospital of St Raphael (2001)
- Resident
- Hospital of St Raphael (2000)
- Fellow
- St. Petersburg State Pavlov Medical University (1997)
- PhD
- Pavlov First State Medical University of St. Petersburg (1997)
- Resident
- St. Petersburg State Pavlov Medical University (1995)
- MD
- Pavlov First State Medical University of St. Petersburg (1993)
Research
Overview
Management of Malignant Hematology - Older Adult Focus; Myeloprolipherative Neoplasms
Medical Subject Headings (MeSH)
ORCID
0000-0002-3657-778X
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Amer Zeidan, MBBS
Xiaomei Ma, PhD
Scott Huntington, MD, MPH, MSc
Rong Wang, PhD
Rory Shallis, MD
Jan Philipp Bewersdorf, MD
Myelodysplastic Syndromes
Myeloproliferative Disorders
Leukemia
Publications
2024
A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol
Palmisiano N, Lee J, Claxton D, Paietta E, Alkhateeb H, Park J, Podoltsev N, Atallah E, Schaar D, Dinner S, Webster J, Luger S, Litzow M. A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol. EJHaem 2024 DOI: 10.1002/jha2.991.Peer-Reviewed Original ResearchConceptsAcute lymphoblastic leukemiaMaximum tolerated doseT-cell acute lymphoblastic leukemiaLymphoblastic lymphomaLymphoblastic leukemiaTreatment-related adverse eventsDose level 3MRD-negative responseDose level 2Dose-limiting toxicityPhase I portionDose-escalation designPhase I/II trialPhase 1 trialPhase I objectivesPhase 2 portionAcute lymphoblastic leukemia subjectsEscalation designTolerated doseLiposomal vincristinePreclinical dataTherapeutic challengeEfficacy outcomesT cellsT-ALLLongitudinal Curriculum to Address Wellness and Professional Development in a Hematology/Oncology Fellowship Program
Srikumar T, Stempel J, Goldberg S, Podoltsev N, Braun D, Lee A, Sanft T. Longitudinal Curriculum to Address Wellness and Professional Development in a Hematology/Oncology Fellowship Program. EMJ Oncology 2024, 1: 37-39. DOI: 10.33590/oncolamj/zgwb5064.Peer-Reviewed Original ResearchPhase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naïve myelofibrosis.
Mascarenhas J, Maher K, Rampal R, Bose P, Podoltsev N, Hong J, Wang X, Kye S, Harrison C. Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naïve myelofibrosis. Journal Of Clinical Oncology 2024, 42: tps6594-tps6594. DOI: 10.1200/jco.2024.42.16_suppl.tps6594.Peer-Reviewed Original ResearchConceptsXPO1 inhibitorsIntent-to-treat populationCo-primary study endpointsBaseline platelet countTreatment-related AEsPlacebo-controlled studyStem cell transplantationPhase 1 portionPhase 3 trialYears of ageNausea prophylaxisOral selinexorIntermediate-1Intermediate-2Anemia responseMF patientsTreatment discontinuationDouble-blindCell transplantationMyeloproliferative neoplasmsSecondary endpointsPlatelet countSpleen volumeRuxolitinib treatmentIWG-MRTLongitudinal curriculum to address wellness and professional development in a hematology/oncology fellowship program.
Srikumar T, Stempel J, Goldberg S, Podoltsev N, Braun D, Lee A, Sanft T. Longitudinal curriculum to address wellness and professional development in a hematology/oncology fellowship program. Journal Of Clinical Oncology 2024, 42: 9004-9004. DOI: 10.1200/jco.2024.42.16_suppl.9004.Peer-Reviewed Original ResearchConceptsNeeds assessmentLongitudinal curriculumPatient Health Questionnaire 2Score of self-efficacyGeneral Self-Efficacy ScaleFellowship programsBaseline needs assessmentFaculty-led sessionsProfessional boundary settingSelf-Efficacy ScaleLevels of depressionProfessional developmentFirst-year fellowsDidactic sessionsPrevent burnoutChi-square testAcademic yearDebriefing sessionsQuestionnaire 2Baseline assessmentSelf-efficacyProfessional development skillsDepressed moodLeadership skillsBurnoutHematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice
Chojecki A, Boselli D, Dortilus A, Hamadeh I, Begley S, Chen T, Bose R, Podoltsev N, Zeidan A, Balmaceda N, Yacoub A, Ai J, Knight T, Ragon B, Shah N, Sanikommu S, Symanowski J, Mesa R, Grunwald M. Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice. Annals Of Hematology 2024, 103: 2837-2843. PMID: 38662203, PMCID: PMC11283405, DOI: 10.1007/s00277-024-05735-7.Peer-Reviewed Original ResearchConceptsFollow-up durationPolycythemia veraThrombotic riskClinical practiceMedian follow-up durationHematocrit controlHematocrit levelsCohort study of patientsLow thrombotic riskUS Food and Drug AdministrationMonths of treatmentRisk of thrombosisStudy of patientsJanus kinase inhibitorsResponse to hydroxyureaFood and Drug AdministrationRed blood cell productionBlood cell productionCytoreductive treatmentPainful splenomegalyDose adjustmentMyeloproliferative neoplasmsPlatelet countThrombotic eventsArterial thrombosesChallenges in management of older patients with chronic myeloid leukemia
Stempel J, Shallis R, Wong R, Podoltsev N. Challenges in management of older patients with chronic myeloid leukemia. Leukemia & Lymphoma 2024, ahead-of-print: 1-14. PMID: 38652861, DOI: 10.1080/10428194.2024.2342559.Peer-Reviewed Original ResearchAltmetricConceptsChronic myeloid leukemiaTyrosine kinase inhibitorsTreatment-free remissionOlder patientsMyeloid leukemiaTyrosine kinase inhibitor dosingGeneration tyrosine kinase inhibitorsManagement of older patientsSecond-line agentsSurvival of patientsSide effect profileFront-line optionPrevalence of comorbiditiesImproved survivalCardiovascular toleranceEffect profileFavorable outcomeKinase inhibitorsPrevent progressionPatientsPersonalized treatmentQuality of lifeTreatment goalsOptimal careDiscontinuation strategiesCost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia
Bewersdorf J, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Stahl M, Stein E, Huntington S, Goshua G, Zeidan A. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia. Leukemia & Lymphoma 2024, 65: 1136-1144. PMID: 38648559, PMCID: PMC11265977, DOI: 10.1080/10428194.2024.2344052.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsCompletion of consolidation therapyFLT3-mutant acute myeloid leukemiaAllogeneic hematopoietic cell transplantationIncremental cost-effectiveness ratioProbabilistic sensitivity analysesImproved overall survivalHematopoietic cell transplantationPartitioned survival analysis modelAcute myeloid leukemiaCost-effectiveness ratioFLT3 inhibitor quizartinibHealth economic implicationsConsolidation therapyInduction chemotherapyAverage wholesale priceOverall survivalCell transplantationContinuous therapyMyeloid leukemiaITD mutationQuizartinibIncremental costCost-effective optionLife yearsProviding 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and Recruitment
Butt A, Christian J, Kress A, Lu B, Hurwitz M, Goldberg S, Podoltsev N, Gilkes L, Lee A. Providing 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and Recruitment. Journal Of Cancer Education 2024, 39: 325-334. PMID: 38430454, DOI: 10.1007/s13187-024-02414-z.Peer-Reviewed Original ResearchCitationsAltmetricConceptsFull-time equivalent supportFull-time equivalentAmerican Council for Graduate Medical EducationCore facultyFellowship programsFellowship educationGraduate Medical EducationImprove job satisfactionCF programPotential unintended consequencesMedical educationSalary supportSurvey respondentsIncreased participationMedical oncologyUnintended consequencesSubspecialty fellowshipsIncreased senseSense of commitmentJob satisfactionFellowshipEducationFaculty involvement
2023
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents
Bewersdorf J, Shallis R, Sharon E, Park S, Ramaswamy R, Roe C, Irish J, Caldwell A, Wei W, Yacoub A, Madanat Y, Zeidner J, Altman J, Odenike O, Yerrabothala S, Kovacsovics T, Podoltsev N, Halene S, Little R, Piekarz R, Gore S, Kim T, Zeidan A. A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents. Annals Of Hematology 2023, 103: 105-116. PMID: 38036712, DOI: 10.1007/s00277-023-05552-4.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsDose-limiting toxicityAcute myeloid leukemiaMarrow complete remissionPhase Ib trialAdverse eventsIb trialDose escalationNCI Cancer Therapy Evaluation ProgramAcute myeloid leukemia refractoryHematologic adverse eventsProtocol-defined responseDose level 1Anti-PD1 therapyAnti-PD1 antibodyDose-escalation designLimited clinical efficacySystems immunology approachHistone deacetylase inhibitor entinostatLeukemia refractoryMCR patientsComplete remissionRespiratory failureSuppressor cellsEscalation designClinical efficacyA randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML
Garcia-Manero G, Podoltsev N, Othus M, Pagel J, Radich J, Fang M, Rizzieri D, Marcucci G, Strickland S, Litzow M, Savoie M, Medeiros B, Sekeres M, Lin T, Uy G, Powell B, Kolitz J, Larson R, Stone R, Claxton D, Essell J, Luger S, Mohan S, Moseley A, Appelbaum F, Erba H. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia 2023, 38: 58-66. PMID: 37935977, DOI: 10.1038/s41375-023-02073-x.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHigh-dose cytarabineAcute myeloid leukemiaDose cytarabineRandomized phase III studyUnfavorable-risk cytogeneticsRandomized multicenter trialOverall remission ratePhase III studyHigh response rateHistone deacetylase inhibitorsInduction therapyFree survivalPrimary endpointRemission rateUntreated patientsIII studyOverall survivalYounger patientsMulticenter trialImproved outcomesMyeloid leukemiaCytogenetic subsetsCytarabineResponse rateHigh doses
Clinical Trials
Current Trials
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
HIC ID2000033381RoleSub InvestigatorPrimary Completion Date12/31/2023Recruiting ParticipantsAn Open-Label Phase 1a/1b Dose Escalation and Expansion Cohort Study of SL-172154 (SIRPα-Fc-CD40L) in Combination With Azacitidine or With Azacitidine and Venetoclax for the Treatment of Subjects With Higher-Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
HIC ID2000032415RoleSub InvestigatorPrimary Completion Date02/28/2024Recruiting ParticipantsBLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination With Conventional Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
HIC ID2000028858RoleSub InvestigatorPrimary Completion Date07/31/2024Recruiting ParticipantsA Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia
HIC ID2000023819RolePrincipal InvestigatorPrimary Completion Date12/31/2028Recruiting ParticipantsGenderBothAge18+ yearsPhase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
HIC ID2000024356RoleSub InvestigatorPrimary Completion Date12/31/2023Recruiting Participants
Academic Achievements and Community Involvement
honor Yale Cancer Center Award for Clinical Excellence
Yale School of Medicine AwardDetails02/15/2022United Stateshonor The David S. Fischer, MD Annual Award for Outstanding Teaching and Mentoring in Hematology
Yale School of Medicine AwardYale Cancer CenterDetails06/09/2021United Stateshonor The David S. Fischer, MD Annual Award for Outstanding Teaching and Mentoring in Hematology
Yale School of Medicine AwardYale Cancer CenterDetails06/14/2017United Stateshonor The David S. Fischer, MD Annual Award for Outstanding Teaching and Mentoring in Hematology
Yale School of Medicine AwardYale Cancer CenterDetails06/15/2011United States
Clinical Care
Overview
Nikolai Podoltsev, MD, PhD, is a hematologist who specializes in treating patients with acute leukemias, or cancers of the blood and bone marrow. These include acute myeloid leukemias, acute lymphoblastic leukemia, myeloid neoplasms, myeloproliferative neoplasms, and chronic myeloid leukemia.
Dr. Podoltsev also cares for patients with aplastic anemia and bone marrow failure syndromes and those with clonal hematopoiesis of indeterminate potential (CHIP), systemic mastocytosis, and hypereosinophilic syndrome. He is the director of the Hematology/Leukemia Tumor Board and represents Yale Cancer Center on National Comprehensive Cancer Network (NCCN) clinical practice guidelines panels, including the Myeloproliferative Neoplasms Panel.
Dr. Podoltsev says he appreciates the relationships he forms with patients and their families. “I enjoy helping them improve their quality of life and taking off the burden of stress when they know they are in the excellent care of our dedicated team,” he says.
Part of the Leukemia Disease Aligned Research Team (DART), Dr. Podoltsev is a principal investigator for multiple clinical trials enrolling patients with acute leukemias and myeloid malignancies.
“We have a number of clinical trials that are investigating drugs that might change the course of many malignant diseases and offering clinical trials is an important part of our mission,” he says.
Clinical Specialties
Fact Sheets
Myeloproliferative Neoplasms
Learn More on Yale MedicineCytogenic Studies for Leukemia Diagnosis
Learn More on Yale MedicineAcute Myeloid Leukemia (AML)
Learn More on Yale MedicineChronic Myeloid Leukemia (CML)
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
News
- June 12, 2024
Yale Medical Oncology-Hematology Fellowship Graduation 2024
- May 28, 2024
Annual Fellows Research Day 2024
- March 25, 2024
Yale’s Post ASH Review
- February 23, 2024
Department of Internal Medicine Promotions and Appointments (February 2024)
Get In Touch
Contacts
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
Events
Everyone Rory Shallis, MD - Nikolai Podoltsev, MD, PhD - Lourdes Mendez, MD, PhD - Joerg Bewersdorf, PhD - Lisa Barbarotta, MSN, APRN-BC, AOCNS